Please find enclosed herewith the Annual Secretarial Compliance Report for the Financial Year 2025-2026.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma Ltd has filed its Annual Secretarial Compliance Report for FY 2025-26, verified by Practising Company Secretaries N L Bhatia & Associates. The report confirms the company has fully complied with all applicable SEBI regulations including SEBI LODR, Insider Trading Regulations, Share Based Employee Benefits Regulations, Takeover Regulations, and other relevant SEBI circulars and guidelines. No deviations, penalties, or regulatory actions were reported against the company, its promoters, directors, or subsidiaries during the review period. The secretarial audit verified compliance with Secretarial Standards, preservation of documents, related party transactions, performance evaluations, and website disclosures. The report was signed on May 19, 2026, and filed with exchanges on May 22, 2026.
This clean compliance report is positive for shareholders as it confirms the company maintains strong corporate governance and regulatory adherence without any violations or regulatory actions. This reinforces investor confidence in the company's operational integrity.